Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III open-label study of FPF3401 in patients with hyposelenemia
jRCT2031220210Phase 3Completed
- Sponsor
- Fujimoto Pharmaceutical
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of trientine hydrochloride in selenium deficiency (2 arms), sponsored by Fujimoto Pharmaceutical. Primary endpoint: Rate of serum selenium normalization and maintenance. Started Jul 2022; status: completed.
02
Drugs
trientine hydrochloride
03
Conditions
selenium deficiency
Beyond the preview
Go deeper on jRCT2031220210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220210.